Literature DB >> 7640211

The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.

E O Aboagye1, A D Lewis, A Johnson, P Workman, M Tracy, I M Huxham.   

Abstract

The novel fluorinated 2-nitroimidazole SR-4554 is undergoing preclinical development as a magnetic resonance spectroscopy and imaging probe for hypoxic tumour cells. We have used electron energy loss spectroscopic analysis (EELS) to show selective reduction and differential subcellular localisation of SR-4554 in human ovarian multicellular spheroids. SR-4554 was demonstrated to be metabolised by these A2780 cells under hypoxic but not under normal aerobic cell culture conditions. The EELS technique illustrated that the relative amount of drug within the cytoplasm of cells from both the inner region (150-160 microns from edge) and outer edge of the spheroid did not differ significantly after an initial 3 h incubation with drug. In contrast, an 8-fold differential between the amount of drug retained in the cytoplasm (primarily ribosomes and endoplasmic reticulum) of cells from the inner vs outer regions of the spheroids was observed following a subsequent 2 h 'chase' culture in drug-free medium. Within cells from the hypoxic region of the spheroid, SR-4554 was mainly associated with the endoplasmic reticulum, nucleus and the cytoplasmic side of intracellular vesicles and also to a lesser extent with the nuclear periphery. Interestingly, the drug was only weakly associated with the mitochondria and plasma membrane of the cells. The characteristics of cellular and subcellular distribution of SR-4554 are consistent with the hypothesis that 2-nitroimidazole compounds undergo hypoxia-mediated enzymatic reduction to reactive species. These reactive species are selectively retained in the cells in which they are metabolised through covalent association with subcellular components. These findings provide additional support for the clinical development of the drug as a non-invasive probe for tumour hypoxia and at the same time illustrate the utility of the EELS technique for examining the heterogeneity of drug distribution both between and within cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640211      PMCID: PMC2034013          DOI: 10.1038/bjc.1995.330

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  The use of parallel EEL spectral imaging and elemental mapping in the rapid assessment of anti-cancer drug localization.

Authors:  I M Huxham; M N Gaze; P Workman; R J Mairs
Journal:  J Microsc       Date:  1992-06       Impact factor: 1.758

2.  Quantitation of hypoxia in multicellular spheroids by video image analysis.

Authors:  G G Miller; M W Best; A J Franko; C J Koch; J A Raleigh
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-04       Impact factor: 7.038

3.  Evaluation of a fluorinated 2-nitroimidazole binding to hypoxic cells in tumor-bearing rats by 19F magnetic resonance spectroscopy and immunohistochemistry.

Authors:  L Kwock; M Gill; H L McMurry; W Beckman; J A Raleigh; A P Joseph
Journal:  Radiat Res       Date:  1992-01       Impact factor: 2.841

4.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.

Authors:  W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

5.  Distribution of misonidazole adducts in 9L gliosarcoma tumors and spheroids: implications for oxygen distribution.

Authors:  A J Franko; C J Koch; D P Boisvert
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

6.  Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro.

Authors:  M I Walton; P Workman
Journal:  Biochem Pharmacol       Date:  1987-03-15       Impact factor: 5.858

7.  Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo.

Authors:  R J Maxwell; P Workman; J R Griffiths
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-04       Impact factor: 7.038

Review 8.  Bioreductive mechanisms.

Authors:  P Workman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

9.  Bioreductive metabolism of AF-2[2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles. Implications for use as hypoxic cell markers.

Authors:  C J Koch; A R Giandomenico; C W Iyengar
Journal:  Biochem Pharmacol       Date:  1993-09-14       Impact factor: 5.858

10.  The detection and measurement of hypoxic cells in solid tumors.

Authors:  J D Chapman
Journal:  Cancer       Date:  1984-12-01       Impact factor: 6.860

View more
  5 in total

Review 1.  New frontiers and developing applications in 19F NMR.

Authors:  Jian-Xin Yu; Rami R Hallac; Srinivas Chiguru; Ralph P Mason
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2012-11-02       Impact factor: 9.795

2.  The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554.

Authors:  E O Aboagye; R J Maxwell; M R Horsman; A D Lewis; P Workman; M Tracy; J R Griffiths
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

3.  Synthesis and characterization of a hypoxia-sensitive MRI probe.

Authors:  Federico A Rojas-Quijano; Gyula Tircsó; Enikő Tircsóné Benyó; Zsolt Baranyai; Huan Tran Hoang; Ferenc K Kálmán; Praveen K Gulaka; Vikram D Kodibagkar; Silvio Aime; Zoltán Kovács; A Dean Sherry
Journal:  Chemistry       Date:  2012-06-27       Impact factor: 5.236

4.  A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.

Authors:  M Shimamura; H Nagasawa; H Ashino; Y Yamamoto; T Hazato; Y Uto; H Hori; S Inayama
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

5.  A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.

Authors:  C P Lee; G S Payne; A Oregioni; R Ruddle; S Tan; F I Raynaud; D Eaton; M J Campbell; K Cross; G Halbert; M Tracy; J McNamara; B Seddon; M O Leach; P Workman; I Judson
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.